INST NAT SANTÉ ET DE LA RECH MÉDICALE has a total of 17 patent applications. Its first patent ever was published in 2008. It filed its patents most often in EPO (European Patent Office), Brazil and Serbia. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS, CANCERFORSKNINGSFONDEN AF 1989 and ARBOR VITA CORP.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 13 | |
#2 | Brazil | 1 | |
#3 | Serbia | 1 | |
#4 | United States | 1 | |
#5 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Medical technology | |
#5 | Environmental technology | |
#6 | Macromolecular chemistry and polymers |
# | Name | Total Patents |
---|---|---|
#1 | Breton Jonathan | 1 |
#2 | Madelmont Jean-Claude | 1 |
#3 | Boumsell Laurence | 1 |
#4 | Maisonial Aurélie | 1 |
#5 | Rbah-Vidal Latifa | 1 |
#6 | Chaffanet Max | 1 |
#7 | Chezal Jean-Michel | 1 |
#8 | Midoux Patrick | 1 |
#9 | Padua Rose Ann | 1 |
#10 | Amara Ali | 1 |
Publication | Filing date | Title |
---|---|---|
EP3076985A1 | Bacterial influence on regulation of appetite via clpb protein mimicry of alpha-msh | |
WO2015078995A1 | Agents for treating cystic fibrosis | |
EP3011333A1 | Markers for long-term kidney graft dysfunction | |
US2015377891A1 | Methods for Predicting the Survival Time of Patients Suffering from Diffuse Large B-Cell Lymphomas | |
EP2744563A1 | Device for the treatment of an ocular disease |